Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib

Market Focus07-10

On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.

On the news front, the company announced on July 1 that its core product Tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial in advanced cholangiocarcinoma, covering over 100 clinical centers across the United States, Europe, and Asia. Tinengotinib is the first and only investigational drug targeting FGFR inhibitor-resistant cholangiocarcinoma to reach the NDA stage globally, having secured FDA Orphan Drug Designation and Fast Track status. Additionally, the company received China NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for mantle cell lymphoma treatment.

Within the Biotechnology sector, multiple peers posted strong gains, with PEGBIO CO-B up 39.78%, 3SBIO up 7.06%, REMEGEN up 6.77%, AKESO up 6.08%, and INNOVENT BIO up 4.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185228112?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185228112","market":"us","top_or_hot":-1,"title":"Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib","media":"Market Focus","content":"<p><p>On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.</p><p>On the news front, the company announced on July 1 that its core product Tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial in advanced cholangiocarcinoma, covering over 100 clinical centers across the United States, Europe, and Asia. Tinengotinib is the first and only investigational drug targeting FGFR inhibitor-resistant cholangiocarcinoma to reach the NDA stage globally, having secured FDA Orphan Drug Designation and Fast Track status. Additionally, the company received China NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for mantle cell lymphoma treatment.</p><p>Within the Biotechnology sector, multiple peers posted strong gains, with PEGBIO CO-B up 39.78%, 3SBIO up 7.06%, REMEGEN up 6.77%, AKESO up 6.08%, and INNOVENT BIO up 4.57%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 11:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.</p><p>On the news front, the company announced on July 1 that its core product Tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial in advanced cholangiocarcinoma, covering over 100 clinical centers across the United States, Europe, and Asia. Tinengotinib is the first and only investigational drug targeting FGFR inhibitor-resistant cholangiocarcinoma to reach the NDA stage globally, having secured FDA Orphan Drug Designation and Fast Track status. Additionally, the company received China NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for mantle cell lymphoma treatment.</p><p>Within the Biotechnology sector, multiple peers posted strong gains, with PEGBIO CO-B up 39.78%, 3SBIO up 7.06%, REMEGEN up 6.77%, AKESO up 6.08%, and INNOVENT BIO up 4.57%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1185228112","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185228112","pubTimestamp":1783653127,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.On the news front, the company announced on July 1 that its core product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"动向提醒|TransThera Sciences-B常规交易涨8.18%，核心产品替奈戈替尼完成III期试验入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.On the news front, the company announced on July 1 that its core product Tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial in advanced cholangiocarcinoma, covering over 100 clinical centers across the United States, Europe, and Asia. Tinengotinib is the first and only investigational drug targeting FGFR inhibitor-resistant cholangiocarcinoma to reach the NDA stage globally, having secured FDA Orphan Drug Designation and Fast Track status. Additionally, the company received China NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for mantle cell lymphoma treatment.Within the Biotechnology sector, multiple peers posted strong gains, with PEGBIO CO-B up 39.78%, 3SBIO up 7.06%, REMEGEN up 6.77%, AKESO up 6.08%, and INNOVENT BIO up 4.57%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185228112","isCrawlerRequest":true}